Raymond James Initiates Coverage On Compass Therapeutics with Outperform Rating, Announces Price Target of $5
Raymond James analyst Dane Leone initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Outperform rating and announces Price Target of $5.
SVB Leerink Initiates Coverage On Compass Therapeutics with Outperform Rating, Announces Price Target of $12
SVB Leerink analyst Andrew Berens initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Outperform rating and announces Price Target of $12.
Wedbush Initiates Coverage On Compass Therapeutics with Outperform Rating, Announces Price Target of $8
Wedbush analyst Robert Driscoll initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Outperform rating and announces Price Target of $8.
Roth Capital Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $15
Roth Capital analyst Tony Butler initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Buy rating and announces Price Target of $15.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Rani Therapeutics Hldgs (NASDAQ:RANI) stock rose 7.36% to $35.0 during Wednesday's after-market session. The company's market cap stands at $690.0 million. As per the news, the Q3 earnings report came out 2 days ago.